MX387336B - Enzimas de clostridium histolyticum y metodos para el uso de los mismos. - Google Patents

Enzimas de clostridium histolyticum y metodos para el uso de los mismos.

Info

Publication number
MX387336B
MX387336B MX2017013257A MX2017013257A MX387336B MX 387336 B MX387336 B MX 387336B MX 2017013257 A MX2017013257 A MX 2017013257A MX 2017013257 A MX2017013257 A MX 2017013257A MX 387336 B MX387336 B MX 387336B
Authority
MX
Mexico
Prior art keywords
enzymes
methods
clostridium histolyticum
polynucleotide
seq
Prior art date
Application number
MX2017013257A
Other languages
English (en)
Inventor
Wayne K Herber
Original Assignee
Endo Global Ventures
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Global Ventures filed Critical Endo Global Ventures
Publication of MX387336B publication Critical patent/MX387336B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24027—Thermolysin (3.4.24.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96419—Metalloendopeptidases (3.4.24)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico recombinante, caracterizada porque comprende; a) un polinucleótido que tiene la secuencia de ácido nucleico de SEQ ID NO: 2 o el complemento de SEQ ID NO: 2, y b) una secuencia reguladora heteróloga vinculada operablemente al polinucleótido.
MX2017013257A 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y metodos para el uso de los mismos. MX387336B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585909P 2012-01-12 2012-01-12
PCT/US2013/020940 WO2013106510A2 (en) 2012-01-12 2013-01-10 Clostridium histolyticum enzymes and methods for the use thereof

Publications (1)

Publication Number Publication Date
MX387336B true MX387336B (es) 2025-03-18

Family

ID=48782075

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014008441A MX351448B (es) 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y métodos para el uso de los mismos.
MX2017013257A MX387336B (es) 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y metodos para el uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014008441A MX351448B (es) 2012-01-12 2013-01-10 Enzimas de clostridium histolyticum y métodos para el uso de los mismos.

Country Status (13)

Country Link
US (8) US9757435B2 (es)
EP (4) EP4276180A3 (es)
JP (5) JP6263755B2 (es)
AU (7) AU2013208028B2 (es)
BR (1) BR112014017229B1 (es)
CA (2) CA2861033C (es)
DK (2) DK3584317T5 (es)
ES (3) ES2904884T3 (es)
HU (2) HUE057423T2 (es)
MX (2) MX351448B (es)
NZ (6) NZ733709A (es)
PT (2) PT3584317T (es)
WO (1) WO2013106510A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3391899T3 (da) 2011-12-14 2020-08-24 Univ Arkansas Afgivelse af terapeutiske midler ved hjælp af et kollagenbindende protein
AU2013208028B2 (en) * 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
RU2540919C1 (ru) * 2013-09-27 2015-02-10 Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" Способ безоперационного лечения контрактуры дюпюитрена iii-iv степени тяжести
PT107276B (pt) * 2013-11-07 2018-06-07 Univ Aveiro Método para produção de colagenase recombinante para digestão de colagénios
WO2017074257A1 (en) * 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
WO2018104540A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
JP2020501545A (ja) * 2016-12-08 2020-01-23 キュアバック アーゲー 肝疾患の処置または予防のためのｒｎａ
WO2018148573A1 (en) 2017-02-10 2018-08-16 The Board Of Trustees Of The University Of Arkansas Collagen-binding agent compositions and methods of using the same
BR112019018277A2 (pt) 2017-03-01 2020-06-30 Endo Ventures Limited aparelho e método para avaliar e tratar celulite
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
CZ308157B6 (cs) * 2017-09-13 2020-01-29 MB PHARMA s.r.o. Kmen bakterie Clostridium histolyticum, kolagenáza připravená s použitím tohoto kmene a její použití
WO2020021330A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021332A2 (en) 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CA3112437A1 (en) 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
CN109355222B (zh) * 2018-11-06 2020-06-02 上海交通大学 对水稻白叶枯病菌具有拮抗作用的芽孢杆菌及分离与应用
KR20210113271A (ko) 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
WO2020164721A1 (de) * 2019-02-14 2020-08-20 Nordmark Arzneimittel Gmbh & Co. Kg Chromatographische aufreinigung von wenigstens einem enzym, ausgesucht aus der gruppe bestehend aus kollagenase typ i, neutrale protease und clostripain
US12403179B2 (en) 2021-02-18 2025-09-02 The Board Of Trustees Of The University Of Arkansas Release of growth factors at wound healing stages
CN112941058B (zh) * 2021-04-02 2023-12-05 重庆科润生物医药研发有限公司 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用
CN113025599B (zh) * 2021-04-02 2023-09-12 重庆科润生物医药研发有限公司 一种重组溶组织梭菌i型胶原酶及其制备方法和应用
EP4448752A4 (en) * 2021-12-14 2025-06-18 Ramot at Tel-Aviv University Ltd. Modified recombinant collagenase, compositions comprising the same and uses thereof in dental related procedures
CN116286753A (zh) * 2023-01-06 2023-06-23 广州达安基因股份有限公司 重组i型胶原蛋白酶及其突变体的制备方法和应用
WO2026028155A1 (en) 2024-08-01 2026-02-05 Endo Biologics Limited Methods of treating plantar fasciitis

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3821364A (en) * 1966-07-08 1974-06-28 Advance Biofactures Corp Process of producing collagenase
JPS5662229A (en) 1979-10-25 1981-05-28 Asahi Glass Co Ltd Electro-optical dimming panel
US4338300A (en) 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
DE3473827D1 (en) 1983-01-05 1988-10-13 Pasteur Institut Highly active collagenolytic preparation and pharmaceutical compositions containing it
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4542065A (en) 1984-05-21 1985-09-17 Ppg Industries, Inc. Chemically treated glass fibers and strands and dispersed products thereof
JPS61289885A (ja) 1985-06-14 1986-12-19 Nitta Zerachin Kk コラゲナ−ゼおよびコラゲナ−ゼの製造方法
JP2898022B2 (ja) 1989-09-05 1999-05-31 株式会社ニッピ コラーゲン分解酵素の製造方法
US5252461A (en) 1990-05-01 1993-10-12 The Regents Of The Univ. Of California Mixed immunoglobulins for detection of rheumatoid factors
CA2047306A1 (en) 1990-07-23 1992-01-24 Milan Holjevac Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase
US5393792A (en) 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5462739A (en) 1991-11-21 1995-10-31 Yeda Research And Development Co., Ltd. Microdelivery device and method for enhanced drug administration to the eye
US5256140A (en) 1992-03-27 1993-10-26 Fallien Cosmeceuticals, Ltd. Composition for levelling skin
CA2138948A1 (en) * 1992-06-22 1994-01-06 Hun-Chi Lin Molecular cloning of the genes responsible for collagenase production from clostridium histolyticum
WO1994016086A1 (en) 1992-12-30 1994-07-21 Bioteknologisk Institut Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same
JP3186881B2 (ja) 1993-02-18 2001-07-11 倉敷紡績株式会社 肝細胞の分離方法
US5332503A (en) 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
US5514340A (en) 1994-01-24 1996-05-07 Magnetix Biotechnology, Inc. Device for separating magnetically labelled cells
CA2189646C (en) 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
HUP9901188A2 (hu) 1995-03-16 1999-08-30 Knoll Aktiengesellschaft Új, meghatározott enzimkeverékek sejtkinyeréshez és sebkezeléshez
US5705170A (en) 1995-10-24 1998-01-06 Plantech International, Inc. Herbal cellulite treatments
US5989888A (en) 1996-01-24 1999-11-23 Roche Diagnostics Corporation Purified mixture of collagenase I, collagenase II and two other proteases
ATE226637T1 (de) 1996-09-06 2002-11-15 Bioteknologisk Inst Milchsäurebakterielles regulierbares expressionssystem
BR9713108A (pt) * 1996-11-19 2004-06-22 Roche Diagnostics Gmbh Colagenase recombinante do tipo i de clostridium histolytucum e o uso da mesma para o isolamento de células e de grupos de células
US5830741A (en) 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US5753785A (en) 1996-12-16 1998-05-19 Fina Technology, Inc. Production of E-B copolymers with a single metallocene catalyst and a single monomer
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
JPH10262658A (ja) 1997-03-28 1998-10-06 Kikkoman Corp ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造
CA2317066A1 (en) 1997-10-03 1999-04-15 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
GB9724802D0 (en) 1997-11-24 1998-01-21 Unilever Plc Antiperspirant or deodorant compoistions
US20020036328A1 (en) 1998-11-16 2002-03-28 William R. Richards, Jr. Offset drain fermi-threshold field effect transistors
FR2788682B1 (fr) 1999-01-26 2001-04-06 Seb Sa Dispositif de thermographie
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
RU2180002C2 (ru) 1999-08-16 2002-02-27 Пермское научно-производственное объединение "Биомед" Способ получения коллагеназы
ATE279175T1 (de) 1999-08-20 2004-10-15 Howard Murad Pharmazeutische zusammensetzungen und verfahren zur verminderung des cellulite auftretens
US6280993B1 (en) * 1999-08-24 2001-08-28 Ichiro Yamato Gene encoding class I collagenase
ITMI991894A1 (it) 1999-09-09 2001-03-09 Carlo Ghisalberti Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso
DK1220830T3 (da) 1999-09-24 2007-07-16 Proteon Therapeutics Inc Anvendelse af elastase til åbning af obstruerede arterier og vener
US7811250B1 (en) 2000-02-04 2010-10-12 Boston Scientific Scimed, Inc. Fluid injectable single operator exchange catheters and methods of use
AU4477001A (en) 2000-04-18 2001-10-30 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
DE60140626D1 (de) 2000-10-20 2010-01-07 Bioneer As Verfahren zur fermentativen herstellung von heterologen genprodukten in milchsäurebakterien
EP1355566B1 (en) 2000-12-18 2012-11-28 Board Of Regents, The University Of Texas System Local regional chemotherapy and radiotherapy using in situ hydrogel
US20030022856A1 (en) 2001-01-30 2003-01-30 The Regents Of The University Of Michigan Method for sustained release local delivery of drugs for ablation of unwanted tissue
EP1402008B1 (de) 2001-07-02 2005-08-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms
GB0124124D0 (en) 2001-10-08 2001-11-28 Medical Res Council Methods of treatment
JP2003284553A (ja) 2002-03-28 2003-10-07 Seikagaku Kogyo Co Ltd 生理活性タンパク質
AU2002345319B2 (en) 2002-06-25 2008-03-06 Ultrashape Ltd. Devices and methodologies useful in body aesthetics
EP1433845A1 (en) * 2002-12-23 2004-06-30 Georg-August-Universität Clostridium tetani collagenase and uses thereof
EP1462519A1 (en) 2003-03-24 2004-09-29 Boehringer Ingelheim Austria GmbH Method and devices for producing biomolecules
JP4205496B2 (ja) 2003-06-19 2009-01-07 三菱化学株式会社 新規カルボニル還元酵素及びこれをコードするｄｎａ、ならびにこれらを利用した光学活性アルコールの製造方法
US7842673B2 (en) 2003-12-17 2010-11-30 The Trustees Of Columbia University In The City Of New York Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
JP4586027B2 (ja) 2004-01-30 2010-11-24 シャイア ファーマシューティカルズ アイルランド リミテッド 組換えアリールスルファターゼａの製造及び精製
PL1732949T3 (pl) 2004-04-07 2010-06-30 Rinat Neuroscience Corp Sposoby leczenia nowotworowego bólu kości przez podawanie antagonisty czynnika wzrostu nerwów
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US7355027B2 (en) 2004-06-16 2008-04-08 Dynport Vaccine Company Llc Bacillus anthracis protective antigen
BRPI0513029A (pt) 2004-07-07 2008-04-22 Lundbeck & Co As H método para produzir uma proteìna de eritropoietina carbamilada, proteìna de eritropoietina carbamilada, composto, composição farmacêutica, métodos de tratamento de uma doença ou condição crÈnica, sub-crÈnica e aguda e de tratamento de uma doença do sistema nervoso central ou sistema nervoso periférico, e, uso de um composto
CA2572765C (en) 2004-07-08 2013-05-21 Amgen Inc. Compound having improved bioefficiency when administered in a multidose regimen
US20060020448A1 (en) 2004-07-21 2006-01-26 Microsoft Corporation Method and apparatus for capitalizing text using maximum entropy
JP4923131B2 (ja) 2004-08-30 2012-04-25 株式会社リコー ログ収集システム、ログ収集装置およびログ収集プログラム
WO2006025226A1 (ja) 2004-08-30 2006-03-09 Daicel Chemical Industries, Ltd. ポリグリセリンモノエーテル及びその製造方法
US20150025420A1 (en) 2004-10-06 2015-01-22 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
DE102004060075A1 (de) 2004-12-14 2006-07-06 Merck Patent Gmbh Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7854929B2 (en) 2005-01-21 2010-12-21 The Research Foundation Of State University Of New York Method for treating lateral epicondylitis using collagenase
KR100989267B1 (ko) 2005-01-21 2010-10-20 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
JP2006254876A (ja) 2005-03-18 2006-09-28 Hokkaido Univ Ｌ−トリプトファン製造法
US20060241673A1 (en) 2005-04-21 2006-10-26 Zadini Filiberto P Subcision device
US20060251581A1 (en) 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US20070003541A1 (en) 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
ITPD20050207A1 (it) 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
US20070031482A1 (en) 2005-08-02 2007-02-08 Ceramoptec Industries, Ind. PDT treatment method for cellulites and cosmetic use
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
EP2001561A2 (en) 2006-03-31 2008-12-17 DSMIP Assets B.V. Novel use of compounds and combinations of compunds for improving the physical appearance
WO2008100833A2 (en) 2007-02-13 2008-08-21 Auxilium International Holdings, Inc. Production of recombinant collagenases colg and colh in escherichia coli
US8617543B2 (en) 2007-02-14 2013-12-31 Yolare Pharmaceuticals, LLC Modified mutant collagenase and its use in fat melting and in scar reduction
KR20100017333A (ko) 2007-05-11 2010-02-16 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 화장료 유효 성분의 전달에 유용한 젤
US9987221B2 (en) 2007-08-23 2018-06-05 Boston Scientific Scimed, Inc. Injectable hydrogel compositions
KR101633612B1 (ko) 2007-10-26 2016-06-27 코닌클리케 필립스 엔.브이. 광각 선택 광 검출기 장치
US20110262508A1 (en) 2007-11-07 2011-10-27 Paul Michael Watt Antimicrobial compositions, formulations and uses thereof
US20100159564A1 (en) * 2007-11-30 2010-06-24 Dwulet Francis E Protease resistant recombinant bacterial collagenases
EP2130551B1 (en) 2008-06-02 2012-06-06 Roche Diagnostics GmbH Improved purification of collagenases from clostridium histolyticum liquid culture
US8236356B2 (en) 2008-06-11 2012-08-07 Roche Diagnostics Operations, Inc. Growth medium for Clostridium histolyticum
EP2306975A4 (en) 2008-07-21 2012-10-31 Otonomy Inc COMPOSITIONS WITH A TAXED RELEASE FOR MODULATING THE EARM STRUCTURE AND THE BORN IMMUNE SYSTEM, AND METHODS OF TREATING EAR OR DISEASE
US8380531B2 (en) 2008-07-25 2013-02-19 Invivodata, Inc. Clinical trial endpoint development process
CA2741334A1 (en) 2008-10-22 2010-04-29 Allergan, Inc. Clinical assessment scales and methods
JP2012508267A (ja) 2008-11-11 2012-04-05 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ セルライトの処置に有用な化合物
CN102216454B (zh) * 2008-11-19 2013-05-29 明治制果药业株式会社 结合了亲和标记物的融合胶原酶及其制造法
IT1397646B1 (it) 2009-12-15 2013-01-18 Seidita Collagenasi ricombinanti di c. histolyticum e metodo per la loro produzione.
WO2011109732A2 (en) 2010-03-05 2011-09-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Reverse thermal gels and uses therefor
WO2011130537A2 (en) 2010-04-14 2011-10-20 Northwestern University Pharmaceutical compositions and methods for digesting atherosclerotic plaques
US20130217789A1 (en) 2010-09-03 2013-08-22 North Carolina Central University Biodegradable liquogel and ph sensitive nanocarriers
ES2385239B1 (es) * 2010-09-30 2013-06-19 Proteos Biotech S.L.U. Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno.
CA2827643C (en) 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
WO2012125948A1 (en) 2011-03-16 2012-09-20 Biospecifics Technologies Corp. Compositions and methods for producing clostridial collagenases
TWI461214B (zh) 2011-06-13 2014-11-21 Univ Chang Gung Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases
EP2768414B1 (en) 2011-10-17 2018-09-26 Sound Surgical Technologies LLC Ultrasonic probe for treating cellulite
PT3581199T (pt) 2011-10-21 2023-08-31 Endo Global Ventures Métodos de tratamento ou redução de paniculopatia edematosa fibroesclerótica
AU2013208028B2 (en) 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
WO2014038097A1 (en) 2012-09-07 2014-03-13 Shiseido Company, Ltd. Method of evaluating cellulite and method of evaluating cellulite-effective drug using fibulin-3 and/or sarcoglycan gamma as an indicator
US20160000890A1 (en) 2013-03-15 2016-01-07 Biospecifics Technologies Corp. Thermosensitive hydrogel collagenase formulations
WO2014144859A1 (en) 2013-03-15 2014-09-18 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN105050580B (zh) 2013-03-15 2017-11-28 玫琳凯有限公司 化妆品组合物及其用途
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
US10729700B2 (en) 2014-06-27 2020-08-04 Medytox Inc. Methods and compositions of bile acids and salts for reduction of fat
AU2017218522A1 (en) 2016-02-08 2018-08-23 OutcomeMD, Inc. Determining a wellness, improvement, or effectiveness score
WO2018077825A1 (en) 2016-10-28 2018-05-03 Merz Pharma Gmbh & Co. Kgaa Treatment of gynoid lipodystrophy
BR112019018277A2 (pt) 2017-03-01 2020-06-30 Endo Ventures Limited aparelho e método para avaliar e tratar celulite
KR20250171475A (ko) 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법

Also Published As

Publication number Publication date
MX351448B (es) 2017-10-16
NZ797997A (en) 2024-05-31
JP2020188810A (ja) 2020-11-26
ES2968836T3 (es) 2024-05-14
US20250041391A1 (en) 2025-02-06
ES2904884T3 (es) 2022-04-06
EP4015627B1 (en) 2023-09-27
NZ750379A (en) 2022-10-28
JP2015506176A (ja) 2015-03-02
AU2016208378A1 (en) 2016-08-18
JP2019103505A (ja) 2019-06-27
EP2802652A2 (en) 2014-11-19
HUE057423T2 (hu) 2022-05-28
AU2021221653B2 (en) 2023-10-05
JP6947888B2 (ja) 2021-10-13
US9757435B2 (en) 2017-09-12
NZ766918A (en) 2023-03-31
EP4015627A1 (en) 2022-06-22
BR112014017229A8 (pt) 2017-07-04
EP3584317A1 (en) 2019-12-25
EP2802652A4 (en) 2015-10-14
AU2021221653A1 (en) 2021-09-23
WO2013106510A3 (en) 2013-10-03
US20200206326A1 (en) 2020-07-02
NZ733709A (en) 2022-10-28
PT3584317T (pt) 2022-01-26
AU2023229488A1 (en) 2023-09-28
AU2026201446A1 (en) 2026-03-19
JP2018075011A (ja) 2018-05-17
CA2861033A1 (en) 2013-07-18
PT2802652T (pt) 2019-09-10
US20250222080A1 (en) 2025-07-10
MX2014008441A (es) 2015-03-13
US20230416717A1 (en) 2023-12-28
US20240252602A1 (en) 2024-08-01
NZ718173A (en) 2017-09-29
ES2740499T3 (es) 2020-02-05
WO2013106510A2 (en) 2013-07-18
AU2016208384B2 (en) 2018-09-13
DK3584317T3 (en) 2022-01-03
BR112014017229A2 (pt) 2017-06-13
US11879141B2 (en) 2024-01-23
CA2970639C (en) 2022-04-26
HUE046160T2 (hu) 2020-02-28
AU2016208378B2 (en) 2018-10-11
EP4276180A3 (en) 2024-01-10
NZ627372A (en) 2016-04-29
AU2019200192A1 (en) 2019-04-04
US11975054B2 (en) 2024-05-07
JP6496386B2 (ja) 2019-04-03
AU2023229488B2 (en) 2025-11-27
AU2019200192B2 (en) 2021-07-01
CA2970639A1 (en) 2013-07-18
JP6263755B2 (ja) 2018-01-24
AU2013208028A1 (en) 2014-08-07
US10603365B2 (en) 2020-03-31
JP7354197B2 (ja) 2023-10-02
JP2022023041A (ja) 2022-02-07
CA2861033C (en) 2017-07-25
AU2016208384A1 (en) 2016-08-11
US20150010532A1 (en) 2015-01-08
EP2802652B1 (en) 2019-06-05
DK2802652T3 (da) 2019-07-15
DK3584317T5 (da) 2022-01-17
AU2013208028B2 (en) 2016-04-28
US20180055918A1 (en) 2018-03-01
US12263209B2 (en) 2025-04-01
US20240269245A1 (en) 2024-08-15
EP4276180A2 (en) 2023-11-15
JP6752309B2 (ja) 2020-09-09
AU2016208384C1 (en) 2023-10-05
BR112014017229B1 (pt) 2022-05-17
EP3584317B1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
MX387336B (es) Enzimas de clostridium histolyticum y metodos para el uso de los mismos.
MX343876B (es) Plantas resistentes al glifosato y metodos asociados.
AR092712A1 (es) Una proteina con actividad cetosa 3-epimerasa
MX2016002306A (es) Promotor u6 de polimerasa iii de soja y metodos de uso.
ES2743232T3 (es) Métodos para la activación o eliminación controlada de células terapéuticas
ECSP16012693A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y polipéptido que contiene aditivo, uso y procedimiento de los mismos
MX2015010875A (es) Microorganismo recombinante para utilizar en metodo con produccion aumentada de producto.
ES2666149T3 (es) Elementos reguladores de plantas y usos de los mismos
MX2015015606A (es) Composiciones detergentes.
AR102950A1 (es) Variantes de lipasa y polinucleótidos que las codifican
PH12014502438A1 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
ES2721309T3 (es) Composición para preparar tagatosa y método para preparar tagatosa a partir de fructosa
MX2017005481A (es) Variantes de interferon a2b.
MX2017010880A (es) Variantes de polipéptidos para el clivaje de la toxina fusario, aditivo que contiene las mismas, uso de las mismas, y método para el clivaje de las toxinas fusario.
IN2014DN07017A (es)
MX375778B (es) Variantes mejoradas de enzimas.
MX389370B (es) Microorganismo recombinante para la produccion mejorada de quimicos finos.
CL2018000164A1 (es) Vector recombinante del virus orf.
MX2017005661A (es) Celulas de mamifero que expresan antigenos de citomegalovirus.
MX2016006277A (es) Secuencia de endolisina kz144 modificada.
MX2017007554A (es) Detergentes y agentes de limpieza que comprende una combinacion de amilasa y proteasa.
MX2017007103A (es) Variantes de lipasa y polinucleotidos que las codifican.
PE20211303A1 (es) Polipeptidos del factor vii de accion corta
MX365416B (es) Xilanasas para solubilizar material que contiene arabinoxilano.
MX341733B (es) Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular.